GlaxoSmithKline isn't sitting still, with two cancer drug approvals and some M&A.
Like all big pharmas reinventing themselves post patent cliff, GlaxoSmithKline is staying busy. It just received FDA approval for two new melanoma drugs and snatched up a Swiss vaccine company for roughly $325 million.
In this video, health-care analyst David Williamson discusses what these two big pieces of news mean for Glaxo investors and also for its competitors.
David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
